Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how quickly margins can stabilize from here.

See our full analysis for Esperion Therapeutics.

With the latest numbers on the table, the next step is to see how this earnings profile lines up against the widely followed bull and bear narratives around Esperion and where those stories may need updating.

Q4 swing to US$61.8 million profit stands out

• Net income moved from a loss of US$31.3 million in Q3 2025 to profit of US$61.8 million in Q4 2025, while trailing twelve month net income is still a loss of US$22.7 million on US$403.1 million of revenue.
• Bulls argue that this move toward profitability fits a longer pattern of improving earnings, since losses have been shrinking at about 22.5% per year over five years. However, the fact that the trailing period remains loss making keeps the bullish story partly unproven.
  • On the bullish side, forecasts pointing to 19.1% annual revenue growth and 54.74% annual earnings growth with a path to profitability within three years align with the sharp improvement seen in Q4 2025.
  • At the same time, the trailing loss of US$22.7 million shows that one strong quarter has not yet translated into consistent profitability, which is the key hurdle bulls need to see cleared.

Bulls point to Q4's sharp turnaround and longer term loss reduction, and try to connect that to faster future growth in cholesterol treatments and international royalties. The trailing loss, however, reminds you that the business model still has to prove it can deliver sustained profits. 🐂 Esperion Therapeutics Bull Case

P/S of 2x versus peers at 6.2x

• The stock is trading on a P/S of about 2x, compared with peer and industry averages of 6.2x and 5.2x, and is noted as being well below a DCF fair value of US$69.15.
• Consensus narrative sees this valuation gap as potential upside if the earnings path plays out, but the current loss making status and balance sheet position explain why the market may be cautious.
  • Support for the balanced view comes from the combination of a low P/S and forecasts for 19.1% revenue growth, which together indicate analysts are expecting the current revenue base of US$403.1 million to grow meaningfully.
  • However, negative shareholders' equity and a trailing net loss of US$22.7 million show why investors might still demand a discount even with the DCF fair value sitting far above the current share price of US$3.14.

Negative equity and recent dilution keep bears engaged

• The risk summary flags negative shareholders' equity, past shareholder dilution over the last year, and higher share price volatility over the past three months, alongside significant insider selling in the same period.
• Bears focus on these balance sheet and trading risks, arguing that even with improving revenue and earnings forecasts the capital structure and recent insider behavior could limit how much investors are willing to pay.
  • Critics highlight that, despite revenue of US$403.1 million over the last twelve months and a swing to US$61.8 million profit in Q4 2025, the company is still loss making over the full period, which can make future funding needs more sensitive to market conditions.
  • They also point to dilution and insider selling as concrete signs that existing holders have already absorbed extra share issuance while some insiders have reduced exposure, which can weigh on sentiment even if forecasts call for earnings to turn positive within three years.

For a closer look at the cautious side of the argument and how these balance sheet and trading risks fit together, skeptics often turn to a focused breakdown of the bear case. 🐻 Esperion Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Esperion Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both optimism and concern in this earnings story, it makes sense to check the underlying data yourself and move quickly to shape your own view by looking through the 4 key rewards and 4 important warning signs.

See What Else Is Out There

Esperion still carries trailing losses, negative shareholders' equity, recent dilution and insider selling, which together keep its balance sheet and risk profile under pressure.

If that mix of weak financial footing and volatility makes you cautious, consider shifting some research time toward companies screened for solid balance sheet and fundamentals stocks screener (44 results) to compare sturdier options side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.